Drreddys Laboratories | RDY - Operating Profit


Drreddys Laboratories reported INR14.33B in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
ANI Pharmaceuticals USD 38.71M 9.58M Mar/2026
Aurora Cannabis CAD -35.79M 19.88M Dec/2025
Bayer EUR 3.53B 2.42B Mar/2026
Canopy Growth CAD -12.66M 1.64M Dec/2025
Cipla INR 9.77B 6.21B Dec/2025
Corcept Therapeutics USD -49.6M 54.09M Mar/2026
Drreddys Laboratories INR 14.33B 2.51B Dec/2025
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Hikma Pharmaceutical USD 348M 161M Dec/2025
Lonza CHF 673M 243M Jun/2025
Novartis USD 4.24B 171M Mar/2026
Pacira USD 4.62M 1.43M Mar/2026
Phibro Animal Health USD 54.99M 2.36M Dec/2025
Prestige Brands USD 75.49M 7M Mar/2026
Richter Gedeon HUF 63.58B 6.08B Sep/2025
Sun Pharmaceuticals INR 33.67B 49.9M Sep/2025
Supernus Pharmaceuticals USD -35.25M 49.07M Mar/2026
Teva Pharmaceutical Industries USD 758M 271M Mar/2026